期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 179, 期 3, 页码 381-399出版社
WILEY
DOI: 10.1111/bph.15605
关键词
adrenomedullin; amylin; calcitonin; CGRP; migraine; pain
资金
- Health Research Council of New Zealand
- Auckland Medical Research Foundation
- University of Auckland
In addition to CGRP, calcitonin family peptides may be therapeutically useful in treating migraines and other pain disorders. Their localization in peripheral pain pathways could play a role in migraines and pain.
The CGRP system has emerged as a key pharmacological target for the treatment of migraine. However, some individuals who suffer from migraine have low or no response to anti-CGRP or other treatments, suggesting the need for additional clinical targets. CGRP belongs to the calcitonin family of peptides, which includes calcitonin, amylin, adrenomedullin and adrenomedullin 2. These peptides display a range of pro-nociceptive and anti-nociceptive actions, in primary headache conditions such as migraine. Calcitonin family peptides also show expression at sites relevant to migraine and pain. This suggests that calcitonin family peptides and their receptors, beyond CGRP, may be therapeutically useful in the treatment of migraine and other pain disorders. This review considers the localisation of the calcitonin family in peripheral pain pathways and discusses how they may contribute to migraine and pain.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据